The purpose of this study is to describe demographic and clinical characteristics of participants who are hospitalized due to coronavirus 2019 (COVID-19), treatment use for COVID-19 and COVID-19 symptoms, and composite outcomes of COVID-19. This study will also compare composite outcomes between COVID-19 participants treated with and without anticoagulant therapy during follow-up period.
Study Type
OBSERVATIONAL
Enrollment
9,282
Local Institution
Minato-ku, Tokyo, Japan
Medical Data Vision
Tokyo, Japan
Distribution of socio-demographic characteristics of COVID-19 patients who are hospitalized from COVID-19: Age
Time frame: At Baseline
Distribution of socio-demographic characteristics of COVID-19 patients who are hospitalized from COVID-19: Age group
Time frame: At Baseline
Distribution of socio-demographic characteristics of COVID-19 patients who are hospitalized from COVID-19: Gender
Time frame: At Baseline
Distribution of socio-demographic characteristics of COVID-19 patients who are hospitalized from COVID-19: Index month
Time frame: At Baseline
Distribution of socio-demographic characteristics of COVID-19 patients who are hospitalized from COVID-19: Height
Time frame: At Baseline
Distribution of socio-demographic characteristics of COVID-19 patients who are hospitalized from COVID-19: Weight
Time frame: At Baseline
Distribution of socio-demographic characteristics of COVID-19 patients who are hospitalized from COVID-19: Body Mass Index (BMI)
Time frame: At Baseline
Distribution of clinical characteristics of COVID-19 patients who are hospitalized from COVID-19: Treatments
Time frame: At Baseline
Distribution of clinical characteristics of COVID-19 patients who are hospitalized from COVID-19: Comorbidities
Time frame: At Baseline
Distribution of clinical characteristics of COVID-19 patients who are hospitalized from COVID-19: Follow-up
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: At Baseline
Distribution of clinical characteristics of COVID-19 patients who are hospitalized from COVID-19: History of thrombosis
Time frame: At Baseline
Distribution of clinical characteristics of COVID-19 patients who are hospitalized from COVID-19: Charlson Comorbidity Index (CCI)
Time frame: At Baseline
Distribution of clinical characteristics of COVID-19 patients who are hospitalized from COVID-19: CCI severity
Time frame: At Baseline
Distribution of clinical characteristics of COVID-19 patients who are hospitalized from COVID-19: Molecular/diagnosis testing
Time frame: At Baseline
Distribution of the use of treatments for COVID-19: Anticoagulation
Time frame: Up to 9 months
Distribution of the use of treatments for COVID-19: Angiotensin-converting enzyme (ACE) inhibitors
Time frame: Up to 9 months
Distribution of the use of treatments for COVID-19: Angiotensin II receptor blockers (ARBs)
Time frame: Up to 9 months
Distribution of the use of treatments for COVID-19: ARBs combination
Time frame: Up to 9 months
Distribution of the use of treatments for COVID-19: Statin
Time frame: Up to 9 months
Distribution of the use of treatments for COVID-19: HIV protease inhibitor
Time frame: Up to 9 months
Distribution of the use of treatments for COVID-19: Non-pharmacological treatment
Time frame: Up to 9 months
Distribution of the use of treatments for COVID-19 symptoms: Anticoagulation
Time frame: Up to 9 months
Distribution of the use of treatments for COVID-19 symptoms: Angiotensin-converting enzyme (ACE) inhibitors
Time frame: Up to 9 months
Distribution of the use of treatments for COVID-19 symptoms: Angiotensin II receptor blockers (ARBs)
Time frame: Up to 9 months
Distribution of the use of treatments for COVID-19 symptoms: ARBs combinations
Time frame: Up to 9 months
Distribution of the use of treatments for COVID-19 symptoms: Statin
Time frame: Up to 9 months
Distribution of the use of treatments for COVID-19 symptoms: HIV protease inhibitor
Time frame: Up to 9 months
Distribution of the use of treatments for COVID-19 symptoms: Non-pharmacological treatment
Time frame: Up to 9 months
Distribution of composite outcomes of COVID-19 patients: In-hospital death
Time frame: Up to 9 months
Distribution of composite outcomes of COVID-19 patients: Overall survival
Time frame: Up to 9 months
Distribution of composite outcomes of COVID-19 patients: Utilization of Extracorporeal membrane oxygenation (ECMO)
Time frame: Up to 9 months
Distribution of composite outcomes of COVID-19 patients: Utilization of mechanical ventilation (invasive & noninvasive)
Time frame: Up to 9 months
Distribution of composite outcomes of COVID-19 patients: Utilization of oxygen therapy
Time frame: Up to 9 months
Distribution of composite outcomes of COVID-19 patients: Intensive care unit/high care unit (ICU/HCU) admission
Time frame: Up to 9 months
Distribution of composite outcomes of COVID-19 patients treated with anticoagulant therapy during the follow-up period
Severity of COVID-19
Time frame: Up to 9 months
Distribution of composite outcomes of COVID-19 patients treated without anticoagulant therapy during the follow-up period
Severity of COVID-19
Time frame: Up to 9 months